- Research
- Open access
- Published:
Identification of key genes associated with cervical cancer based on bioinformatics analysis
BMC Cancer volume 24, Article number: 897 (2024)
Abstract
Background
Cervical cancer has extremely high morbidity and mortality, and its pathogenesis is still in the exploratory stage. This study aimed to screen and identify differentially expressed genes (DEGs) related to cervical cancer through bioinformatics analysis.
Methods
GSE63514 and GSE67522 were selected from the GEO database to screen DEGs. Then GO and KEGG analysis were performed on DEGs. PPI network of DEGs was constructed through STRING website, and the hub genes were found through 12 algorithms of Cytoscape software. Meanwhile, GSE30656 was selected from the GEO database to screen DEMs. Target genes of DEMs were screened through TagetScan, miRTarBase and miRDB. Next, the hub genes screened from DEGs were merged with the target genes screened from DEMs. Finally, ROC curve and nomogram analysis were performed to assess the predictive capabilities of the hub genes. The expression of these hub genes were verified through TCGA, GEPIA, qRT-PCR, and immunohistochemistry.
Results
Six hub genes, TOP2A, AURKA, CCNA2, IVL, KRT1, and IGFBP5, were mined through the protein-protein interaction network. The expression of these hub genes were verified through TCGA, GEPIA, qRT-PCR, and immunohistochemistry, and it was found that TOP2A, AURKA as well as CCNA2 were overexpressed and IGFBP5 was low expression in cervical cancer.
Conclusions
This study showed that TOP2A, AURKA, CCNA2 and IGFBP5 screened through bioinformatics analysis were significantly differentially expressed in cervical cancer samples compared with normal samples, which might be biomarkers of cervical cancer.
Background
Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of death from cancer in women worldwide in 2020. According to statistics, it was estimated that there were 604,127 new cases and 341,831 deaths worldwide in 2020, accounting for 6.5% of new female cancer cases and 7.7% of deaths [1, 2]. The most common types of cervical cancer are squamous cell carcinoma (SCC) and adenocarcinoma (ADC), accounting for 70% and 25%, respectively. And a less common type of cervical cancer is adenosquamous carcinoma (ADSC) [3, 4]. Acknowledgedly, HPV is an important factor that causes cervical cancer [5]. Due to cytological screening, HPV vaccination and other methods, the incidence of cervical cancer is greatly reduced [3, 6]. The treatment methods of cervical cancer include surgery, chemotherapy and radiotherapy [7]. Although the level of treatment has improved in recent years, the long-term prognosis of cervical cancer is still poor because of drug resistance and recurrence.
Most patients with localized cervical cancer can be cured by surgery, and the 5-year survival rate is 91.5%. However, patients with metastatic cervical cancer still have no good treatment methods, and the 5-year survival rate is low, only 17% [4, 8]. In recent years, with the development of high-throughput sequencing technology and bioinformatics analysis methods, the role of differentially expressed genes (DEGs) in cervical cancer has been continuously explored. Therefore, mining DEGs from the molecular level has become a necessary choice to provide new ideas for the diagnosis and prognosis of cervical cancer.
In this study, two microarray datasets (GSE63514 and GSE67522) were downloaded from the GEO database using bioinformatics methods to screen DEGs. The DEGs were performed to Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes ( KEGG) pathway enrichment analysis. And then a protein-protein interaction (PPI) network was constructed to screen hub genes. The GSE30656 dataset was downloaded from the GEO database to screen differentially expressed miRNAs (DEMs). The target genes of DEMs were predicted through the three websites of Targetscan, miRDB and miRTarBase. The final DEGs were screened by the intersection of the hub genes and the target genes. The Cancer Genome Atlas (TCGA) and Gene Expression Profile Interaction Analysis (GEPIA) database were used to identified these gene screened. RT-qPCR and immunohistochemistry were used to verify the results.This study provided new perspectives and ideas for further research on the mechanism of cervical cancer occurrence and development.
Materials and methods
Data collection
Figure 1 depicted the study fowchart.
The cervical cancer datasets were download from the GEO database (https://www.ncbi.nlm.nih.gov/geo/). The search terms included “cervical cancer”, “homo sapiens”, “expression profiling by array”, and we chose the datasets including normal tissues and tumor tissues. GSE63514 is a gene expression analysis of cervical cancer progression on 24 normal specimens and 28 cancer specimens. GSE67522 includes 22 normal and 28 cancers specimens to identify the probably functionally relevant pathways in cervical cancer progression. To exclude the effect of individual heterogeneity and ensure more accurate results, we chose these two datasets for further analysis. Then we searched for “cervical cancer”, “homo sapiens”, “Non-coding RNA profiling by array”, and finally GSE30656 dataset was selected for analysis. GSE30656 includes 10 squamous cell carcinomas of the cervix, 9 adenocarcinomas of the cervix, and 10 cervical squamous epithelial samples with normal histology, which were used to identify miRNAs associated with cervical carcinogenesis.
Screening of DEGs and DEMs
GEO2R (https://www.ncbi.nlm.nih.gov/geo/info/geo2r.html) performed comparisons on original submitter-supplied processed data tables using the GEOquery and limma R packages from the Bioconductor project. Two mRNA datasets (GSE63514 and GSE67522) and miRNA datasets (GSE30656) were analyzed using GEO2R. We defined DEGs that met the two screening conditions of adjusted (adj.) p value < 0.05 as well as |log2 fold change (log2FC)| > 1.5 were statistically significant. The DEGs were analyzed with Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/index.html), and then the common up-regulated and down-regulated DEGs were obtained. The miRNAs with the largest difference multiple were selected as the object of follow-up study.
Functional enrichment analysis of DEGs
GO enrichment analysis and KEGG signaling pathway analysis were performed on the above DEGs by DAVID 6.7 (https://david-d.ncifcrf.gov/) to understand the biological functions of these DEGs [9]. Fill in gene ID in “Enter Gene List”, select “OFFICIAL_GENE_SYMBOL” in “select identifier”, select “Homo sapiens” in “Select species”. Finally, the KEGG results were visualized by R language. Corrected P-Value < 0.05 indicated statistical difference.
PPI network construction
Protein-protein interaction analysis can serve as an entry point to better explain the relationships between different proteins at the genome scale, and may help provide new insights into the functional interpretation of proteins. STRING (version 11.0, https://string-db.org/) database, which has 5090 organisms and 24.6 million proteins, was used to construct the PPI network [10]. “Network type” was set to “full STRiNG network (the edges indicate both functional and physical protein associations)”. “Meaning of network edges” was set to “evidence”. “Minimum required interaction score” was set to “medium confidence (0.400)”. “Max number of interactors to show” was set to “none”. The analyzed data was imported into Cytoscape (version 3.6.1, http://www.cytoscape.org/) software, and the top 10 genes were selected through 12 algorithms [11], and then the hub genes with the most frequency were screened. The hub genes with the highest score were selected according to Degree score. These screened hub genes were used as research objects.
Screening of DEMs target genes
TargetScan (http://www.targetscan.org/), miRTarBase (http://mirtarbase.cuhk.edu.cn/php/index.php) and miRDB (http://mirdb.org/) were applied to predict the potential target genes of DEMs. The target genes of DEMs were screened using Venny online software. Conditions for screening target genes of TargetScan: Select “Human” in “Select a species”, and fill in “miRNA” in “Enter a microRNA name”. Conditions for screening target genes of miRTarBase: Select “Human” in “Species”, and then click “Submit”. Conditions for screening target genes of miRDB: Select “Human” in “Search by miRNA name”, and then fill in the miRNAs to be searched.
ROC curve and nomogram analysis
The receiver operating characteristic (ROC) curve was a simple, efficient and comprehensive tool. It constructed a monotonically increasing curve by connecting the values of the true positive rate and the false positive rate at different cutoff points or thresholds. The area under the curve (AUC) could be used as an indicator to measure the diagnostic effect. The larger the area, the more effective the classification method was. Nomogram analysis transformed the complex regression equation into a visual graph, and making the results of the prediction model more readable. ROC curve was drawn by GraphPad Prism 9.0.0, and the nomogram was drawn by the Hmisc and rms packages of R language.
Validation of hub genes and DEMs
TCGA (The Cancer Genome Atlas) is a large-scale cancer research project jointly established by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). It molecularly characterized over 20,000 primary cancer and matched normal samples spanning 33 cancer types, which is a free and open cancer genetic research database. GEPIA (http://gepia.cancer-pku.cn/) is a cancer data analysis website developed by the Peking University team, which is based on TCGA and Genotype-Tissue Expression (GTEx) database.
The TCGA database and GEPIA were used to verify the expression of hub genes in cervical cancer samples, and RT-qPCR technology was used to verify the relative mRNA expression levels of hub genes and miRNA expression levels of DEMs in cervical cancer cells.
Cell lines and cell culture
Ect1/E6E7 cell (Human cervix immortalized squamous cells) as well as Hela and SiHa cell (Human cervical cancer cell lines) were obtained from Chinese Academy of Sciences Cell Bank/Stem Cell Bank (Shanghai, China).These cell lines were cultured in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin at 37˚C in a humidified atmosphere of 5% CO2. 500,000 Ect1/E6E7 and Hela as well as SiHa cells were respectively seeded in the wells of the six-well plate for RNA extraction, and the experiment was repeated three times.
RNA extraction and RT-qPCR
miRNA extraction and RT-qPCR: Total RNA was extracted from the cultured cells using Trizol Reagent (Solaibao Technology Co. LTD, Beijing, China) following the manufacturer’s protocol. For the detection of miRNA expression, complementary DNA (cDNA) was synthesized with miRNA 1st Strand cDNA Synthesis Kit by stem-loop (Vazyme Biotech Co.,Ltd, Nanjing, China) and qPCR was performed with miRNA Universal SYBR® qPCR Master Mix (Vazyme Biotech Co.,Ltd). The relative expression level of miRNA was normalized to U6 small nuclear RNA (U6).
mRNA extraction and RT-qPCR: To analyze mRNA expression levels, total RNA was reversed transcribed to cDNA using FastKing RT Kit with gDNase (Tiangen Biochemical Technology Co., LTD, Beijing, China) and qPCR was performed with Hieff® qPCR SYBR Green Master Mix (Low Rox Plus). The relative expression level of mRNA were normalized to β-ACTIN.
The operating conditions used for qPCR of miRNA and mRNA were as follows: hold stage was 95˚C for 5 min, PCR stage were the 40 cycles of 95˚C for 10 s and 60˚C for 30 s, and the melt curve stage were 95˚C for 15 s and 60˚C for 1 min as well as 95˚C for 15 s. All experiments were performed in triplicate. Data were analyzed using the comparative Ct (2-ΔΔCt) method for quantification. The primer sequences were shown in Table 1.
Immunohistochemical analysis
The protein expression of hub gene in cervical cancer tissue was analyzed through the Human Protein Atlas database (http://www.proteinatlas.org). According to the staining intensity of protein in the tissue and percentage of stained cells, compared the protein expression of the DEGs in normal and tumor tissue, and captured representative immunostaining images.
Results
Screening for differentially expressed genes
Cervical cancer and normal cervical epithelial tissues were compared in the GSE63514 and GSE67522 dataset by GEO2R. There were 1975 DEGs in GSE63514, including 1198 up-regulated genes and 777 down-regulated genes. GSE67522 screened 564 DEGs with 237 up-regulated genes and 327 down-regulated genes. The volcano plots of these DEGs for each dataset were shown in Fig. 2A-B. The above DEGs were analyzed by Venny 2.1.0 and it was found that there were 153 co-upregulated genes and 144 co-downregulated genes, as shown in C-D of Fig. 2. Detailed results were shown in Table S1. GEO2R was used to analyze the GSE30656 dataset, and the volcano plot of DEMs was shown in Fig. 2E. miR-21 and miR-203 with the largest difference multiple were selected as subsequent research objects. The information of the three datasets were shown in Table 2.
GO functional annotation and KEGG enrichment analysis of DEGs
The GO functional annotation of the screened DEGs were obtained by using the DAVID database including the following three parts: molecular function (MF), cellular component (CC) and biological process (BP). The top 15 up-regulated GO terms and down-regulated GO terms were summarized in Table 3. As shown in Fig. 3A, up-regulated DEGs were mainly enriched in protein binding (MF), nucleus (CC), and cell division (BP). The down-regulated DEGs were mostly concentrated in serine-type endopeptidase activity (MF), extracellular exosome (CC) and proteolysis (BP), as shown in Fig. 3B. The KOBAS online analysis tool was used to analyze the KEGG pathway of DEGs, and the bubble map was drawn using R language, as shown in Fig. 3C. The KEGG pathway of DEGs were mainly enriched in Cell cycle and Metabolic pathways, and the enrichment pathway of DEGs were shown in Table 4.
Establishment of PPI network and screening of hub genes
The 153 up-regulated genes and 144 down-regulated genes screened were analyzed using the STRING online database, and then PPI networks were constructed for these genes, as shown in Fig. 4A-B. The PPI network was further analyzed by Cytoscape software. Based on 12 algorithms (EcCentricity, DMNC, MCC, MNC, Betweenness, ClusteringCoefficient, BottleNeck, Closeness, Radiality, Stress, EPC and Degree) in cytoHubba plugin of Cytoscape, we selected the top 10 hub genes of the 12 algorithms respectively, and then obtained AURKA and CCNA2 (the up-regulated genes) and KRT1 (the down-regulated gene) with the most frequent occurrences from the above screened genes. Detailed results were shown in Table S2 and Fig. 4C-D. At the same time, TOP2A (the up-regulated gene) and IVL (the down-regulated gene) with the highest Degree score were selected as hub genes for follow-up study.
Screenning the target genes of miR-21and miR-203
Three websites, TargetScan, miRTarBase and miRDB, were used to screen the target genes of miR-21 and miR-203, which miR-21 included miR-21-3p and miR-21 -5p, and miR-203 included miR-203a-3p, miR-203a-5p, miR-203b-3p and miR-203b-5p (the details of target genes in table S3-S4). 184 common target genes were selected by tooking the intersection of these target genes, and the results and details of these genes were shown in Fig. 5A as well as Table S5. The 184 target genes were intersected with the hub genes (53 up-regulated and 30 down-regulated, seen Table S1) screened by the above 12 algorithms to screen out IGFBP5, and the results were shown in Fig. 5B.
Assessment of 6 hub genes for the predictive capabilities
ROC curve and nomogram analysis of the GES63514 dataset were performed to assess the predictive capabilities of the identified genes. Using the Hmisc and rms packages, we developed the nomogram model of cervical cancer based on the hub genes. As shown in Fig. 6A, in the GSE63514 dataset, the AUC values of TOP2A, AURKA, CCNA2, IVL, KRT1, and IGFBP5 were 0.9315, 0.9048, 0.8140, 0.8810, 0.8021, and 0.7336, respectively. And the combined predictive value of the 6 genes was 0.9896. The results indicated that all 6 genes had predictive value in cervical cancer, and the combined predictive value of the 6 genes was more significant. As shown in Fig. 6B, the value range of these 6 genes and their contribution to the risk of cervical cancer were visualized. Based on the values of different genes in the sample, the total score can be calculated and the risk of cervical cancer can be predicted.
Validation of hub genes
First, we verified the six screened genes which were TOP2A, AURKA, CCNA2, IVL, KRT1, and IGFBP5, in GSE63514 and GSE67522 datasets. As shown in Fig. 7A-B, the TOP2A, AURKA and CCNA2 in cervical cancer were significantly increased, while IVL, KRT1, and IGFBP5 were significantly decreased, compared with normal tissues, which was consistent with the screening results. Next, we verified these 6 genes through the TCGA database.We found that TOP2A, AURKA, CCNA2 were overexpressed and IGFBP5 was low expression in cervical cancer, but IVL was overexpressed in cervical cancer, which was contrary to the result of GEO dataset in Fig. 8 and KRT1 was no significant difference in cervical cancer tissue and normal tissue. Then, we verified the expression of these 6 genes through GEPIA (merged the normal samples of cervical tissues in the GTEx database). As shown in Fig. 9, compared with normal tissues, TOP2A, AURKA, CCNA2 and IVL in cervical cancer tissues were significantly up-regulated, while IGFBP5 was significantly down-regulated, and there was no statistical difference in the expression of KRT1 in cervical cancer tissues and normal tissues, which were consistent with the analysis results of TCGA database. We performed staging analysis for these six genes by GEPIA. As shown in Figure S1, the cervical cancer patients with clinic Stage II, Stage III or Stage IV had a higher expression level of AURKA, CCNA2, IVL and KRT1 than Stage I. Since the database analysis results were inconsistent, we detected the relative expression levels of the 6 genes in cervical cancer cell lines by qRT-PCR. As shown in Fig. 10, the expressions of TOP2A and AURKA were significantly increased in Hela cell, but the increased expressions of TOP2A and AURKA in SiHa cell were no statistical significance compared to human cervix immortalized squamous cell. And CCNA2 were significantly increased in Hela cell and SiHa cell. The expression of IGFBP5 was significantly decreased in Hela cell, but the decreased expression in SiHa cell was no statistical significance compared to Ect1/E6E7 cell. The expression of KRT1 was increased in cervical cancer cell, but there was no statistical significance compared with normal cell, and, interestingly, this was contrary to the trend of KRT1 expression in GEO datasets. The expression of IVL was decreased in cervical cancer cell, but there was no statistical significance, which was consistent with the expression trend in GEO datasets.
Validation of protein
Therefore, immunohistochemical analysis of TOP2A, AURKA, CCNA2, KRT1, IVL and IGFBP5 were performed through The Human Protein Atlas database and it revealed that these protein were positive in cervical cancer tissues except IGFBP5. The antibody HPA006458 was used to detect TOP2A at medium intensity with the proportion of stained cells < 25% in normal cervix tissues, while in cervical cancer tissues, it showed high intensity staining with the proportion of stained cells ranging from 25 to 75%. The antibody CAB001454 did not detect AURKA in normal cervix tissues, and showed moderate intensity staining in cervical cancer tissues, with the proportion of stained cells ranging from 25 to 75%. The antibody CAB000114 was used to detect CCNA2 at medium intensity with the proportion of stained cells < 25% in normal cervix tissue, and it showed high intensity staining in cervical cancer tissue, with the proportion of stained cells from 25 to 75%. The antibody CAB002153 did not detect KRT1 in normal cervix tissues, and it was stained with low intensity in cervical cancer tissues, and the proportion of stained cells was < 25%. The antibody HPA055211 was used to detect IVL at medium intensity with the proportion of stained cells < 25% in normal cervix tissues and cervical cancer tissues. Immunohistochemical results of IGFBP5 were not included in this database. From the above results, it can be seen that the protein expression of TOP2A, AURKA and CCNA2 were significantly increased in cervical cancer tissues, as shown in Fig. 11.
Expression of miR-21 and miR-203 in cervical cancer cell
The expression of miR-21-3p, miR-21-5p, miR-203a-3p, miR-203a-5p, miR-203b-3p and miR-203b-5p were detected in cervical cancer cells by qRT-PCR. As shown in Fig. 12, compared with human cervix immortalized squamous cell, the expression of miR-21-3p was up-regulated in Hela cell, but there was no statistical significance. MiR-21-5p was significantly up-regulated in SiHa cell compared to Ect1/E6E7 cell, while miR-203a-3p, miR-203a-5p, miR-203b-3p and miR-203b-5p were significantly down-regulated in SiHa and Hela cell.
Discussion
GSE63514 included 24 normal and 28 cancers specimens, which were cryosecrtioned and used for laser-capture, RNA extraction, two rounds of T7-mediated amplification, and cRNA biotinylation. Bio-cRNA was hybridized to Affymetrix U133-Plus2.0 arrays, and scanned signals were processed through GC-RMA [12]. GSE67522 included 22 normal and 28 cancers specimens. Total RNA obtained from HPV negative histologically normal controls and HPV16 positive cervical cancers having either low or high HOTAIR expression levels were compared to identify transcriptome level differences [13, 14].In this study, six DEGs, TOP2A, AURKA, CCNA2, KRT1, IVL and IGFBP5, were screened out through the GSE63514 and GSE67522 datasets. TOP2A, AURKA and CCNA2 were overexpressed in cervical cancer, while IVL and IGFBP5 were low expression in cervical cancer. However, interestingly, the TCGA database and GEPIA online website analysis showed that TOP2A, AURKA, CCNA2 and IVL were overexpressed and IGFBP5 was low expression in cervical cancer, and there was no statistical difference in the expression of KRT1 in cervical cancer tissue and normal tissue. The above inconsistent results may be due to the small number of normal tissue samples in TCGA and GEPIA database, which led to the bias in statistical analysis. Next, we extracted RNA from cultured cell to verify the expression of these 6 genes in cervical cancer cell by RT-qPCR. The results showed that the expression of TOP2A, AURKA and CCNA2 were statistically increased in cervical cancer cell, while the expression of IGFPB5 was statistically decreased in cervical cancer cell, which was consistent with the results of GEO dataset and TCGA database. The increased expression of KRT1 in cervical cancer cell was not statistically significant, and interestingly, which was contrary to the expression trend of KRT1 in GEO datasets. The expression of IVL was decreased in cervical cancer cell, but there was no statistical significance, which was consistent with its expression trend in GEO dataset. The KRT1 was interesting and deserved further study. Immunohistochemical results showed that the expression of TOP2A, AURKA, CCNA2 and KRT1 were increased in cervical cancer tissue, and the expression of IVL was no significant difference between cervical cancer tissue and normal cervix tissue.
TOP2A (DNA topoisomerase II alpha) encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance [15]. It was reported that the expression of TOP2A was up-regulated in cervical cancer and it promoted cell migration, invasion and epithelial-mesenchymal transition in cervical cancer by activating the PI3K/AKT signaling [16].
The protein encoded by AURKA (aurora kinase A) is a cell cycle-regulated kinase that appears to be involved in microtubule formation and/or stabilization at the spindle pole during chromosome segregation. The encoded protein is found at the centrosome in interphase cells and at the spindle poles in mitosis. This gene may play a role in tumor development and progression [17]. AURKA was overexpressed and associated with lymph-node metastasis in cervical cancer patients [18].
The protein, cyclin A2, encoded by CCNA2 belongs to the highly conserved cyclin family. This protein binds and activates cyclin-dependent kinase 2 and thus promotes transition through G1/S and G2/M [19].It was reported that CCNA2 was up-regulated and the high CCNA2 expression promoted cell cycle progression in cervical cancer [20].
The protein encoded by KRT1 (keratin 1) is a member of the keratin gene family, which is located in the epithelial prickle and granular cell layer. KRT1 has been proved to regulate kinase activity and participate in angiogenesis, fibrinolysis and oxidative stress [21]. so far, there are few studies on KRT1 in cervical cancer.
Involucrin encoded by IVL is a component of the keratinocyte crosslinked envelope, which is found in the cytoplasm and crosslinked to membrane proteins by transglutaminase [22]. IVL was significantly downregulated in cervical intraepithelial neoplasia and ultimately squamous cell carcinoma [23].
Insulin like growth factor binding protein 5 encoded by IGFBP5 is involved in several processes, including cellular response to cAMP and regulation of smooth muscle cell migration as well as regulation of smooth muscle cell proliferation [24, 25]. IGFBP5 was downregulated in cervical squamous cell carcinomas tissues samples [26]. IGFBP5 expression was up-regulated in response to progression of CIN and down-regulated in invasive cervical carcinoma [27].
miRNA are short (20–24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNA can be divided into three different forms, which include primary (pri‑) miRNA, precursor (pre‑) miRNA and mature miRNA. The mature miRNA called miRNA-3p and miRNA-5p are derived from the 3’ or 5’ arm of their pre-miRNA, respectively. Therefore, all pre‑miRNAs can produce both types of mature miRNA [28, 29]. In this study, miR-21 (up-regulated) and miR-203 (down-regulated) were screened out through the GSE30656 dataset, which analysed 10 squamous cell carcinomas of the cervix, 9 adenocarcinomas of the cervix and 10 cervical squamous epithelial samples with normal histology using single channel (Cy3) miRNA microarrays from Agilent [30]. MiR-21 includes miR-21-3p and miR-21 -5p, and miR-203 family includes miR-203a-3p、miR-203a-5p、miR-203b-3p and miR-203b-5p. The miR-21-3p and miR-21-5p were up-regulated in cervical cancer cells, while miR-203a-3p, miR-203a-5p, miR-203b-3p and miR-203b-5p were down-regulated in cervical cancer cells by RT-qPCR, which was consistent with the analysis results of GSE30656 dataset. MiR-21 acts as an oncogene in cancer by regulating many pathways involved in tumor development. MiR-21 was up-regulated and regulated multiple signaling pathways in cervical cancer, including TNF-α/caspase-3/caspase-8, PI3K/AKT/mTOR, and RAS/MEK/ERK pathways [31]. MiR-203 in the cervical cancer group was significantly lower than control group [32]. And miR-203 was involved in cell cycle regulation and suppressed cervical cancer cell migration and invasion [33].
The advantage of this study was that it innovatively combined mRNA and miRNA datasets to screen hub genes, and the 6 selected hub genes were verified by RT-qPCR and immunohistochemistry. It was found that TOP2A, AURKA, CCNA2 and IGFBP5 could be all potential tumor markers for cervical cancer. It was worth noting that IGFBP5 was neither the top 10 DEGs screened by the mRNA datasets nor the top 10 target genes screened by the miRNA dataset, but it was the only gene that appeared in both screening pathways at the same time, so it was selected as a hub gene. This provided a new idea for mining hub genes.
However, Our study also had some limitations. For example, all the data analyzed in this study were from bioinformatics databases. And this study only screened out hub genes related to cervical cancer tumors, but their internal influencing mechanisms and interconnections were not clear. It is required further research in cervical cancer by clinical tissues and cervical cancer cell lines in vivo and in vitro experiments.
Conclusions
In short, through bioinformatics analysis, as well as qRT-PCR and immunohistochemistry, this study found that TOP2A, AURKA, CCNA2 were overexpressed and IGFBP5 was low expression in cervical cancer, which might be potential tumor markers and further research is needed to confirm their clinical value.
Data availability
The datasets that support the findings of this study are available in the GEO database (https://www.ncbi.nlm.nih.gov/geo/).
Abbreviations
- DEGs:
-
Differentially expressed genes
- CC:
-
Cervical cancer
- SCC:
-
Squamous cell carcinoma
- ADC:
-
Adenocarcinoma
- ADSC:
-
Adenosquamous carcinoma
- GO:
-
Gene Ontology
- KEGG:
-
Kyoto Encyclopedia of Genes and Genomes
- PPI:
-
Protein-protein interaction
- DEMs:
-
Differentially expressed miRNAs
- TCGA:
-
The Cancer Genome Atlas
- GEPIA:
-
Gene Expression Profile Interaction Analysis
- ROC:
-
Receiver Operating Characteristic
- AUC:
-
Area Under the Curve
- cDNA:
-
Complementary DNA
- MF:
-
Molecular Function
- CC:
-
Cellular Component
- BP:
-
Biological Process
- TOP2A:
-
DNA Topoisomerase II Alpha
- AURKA:
-
Aurora Kinase A
- KRT1:
-
Keratin 1
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49.
Yu S, Li X, Zhang J et al. Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of patients with cervical cancer[J]. Front Immunol. 2021, 12.
He J, Huang B, Zhang K, et al. Long non-coding RNA in cervical cancer: from biology to therapeutic opportunity[J]. Biomed Pharmacother. 2020;127:110209.
Adiga D, Eswaran S, Pandey D, et al. Molecular landscape of recurrent cervical cancer[J]. Crit Rev Oncol Hematol. 2021;157:103178.
Burk R, Terai M, Gravitt P et al. Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix[J]. 2003, 63 (21):7215–20.
Small W Jr., Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis[J]. Cancer. 2017;123(13):2404–12.
Ma H, Liu Z, Li H et al. Bioinformatics analysis reveals MCM3 as an important prognostic marker in cervical cancer[J]. Comput Math Methods Med. 2021, 2021:8494260.
Ferrall L, Lin KY, Roden RBS, et al. Cervical cancer immunotherapy: facts and Hopes[J]. Clin Cancer Res. 2021;27(18):4953–73.
Huang DW, Sherman BT, Tan Q et al. DAVID Bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists[J]. Nucleic Acids Res. 2007, 35 (Web Server issue):W169-175.
Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res. 2019;47(D1):D607–13.
Chia-Hao C, Shu-Hwa C, Hsin-Hung W et al. cytoHubba: identifying hub objects and sub-networks from complex interactome[J]. 2014(0).
den Boon JA, Pyeon D, Wang SS, et al. Molecular transitions from papillomavirus infection to cervical precancer and cancer: role of stromal estrogen receptor signaling[J]. Proc Natl Acad Sci U S A. 2015;112(25):E3255–3264.
Sharma S, Mandal P, Sadhukhan T, et al. Bridging links between long noncoding RNA HOTAIR and HPV oncoprotein E7 in Cervical Cancer Pathogenesis[J]. Sci Rep. 2015;5:11724.
Saha S, Chowdhury R, Mondal N et al. Expression signatures of HOX cluster genes in cervical cancer pathogenesis: impact of human papillomavirus type 16 oncoprotein E7[J]. 2017, 8 (22):36591–602.
Morimoto T. Type II DNA topoisomerases cause spontaneous double-strand breaks in genomic DNA[J]. Genes. 2019;10:11.
Wang B, Shen Y, Zou Y, et al. TOP2A promotes Cell Migration, Invasion and epithelial-mesenchymal transition in Cervical Cancer via activating the PI3K/AKT Signaling[J]. Cancer Manag Res. 2020;12:3807–14.
Du R, Huang C, Liu K, et al. Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy[J]. Mol Cancer. 2021;20(1):15.
Shao S, Wang C, Wang S, et al. Hsa_circ_0075341 is up-regulated and exerts oncogenic properties by sponging mir-149-5p in cervical cancer[J]. Biomedicine & Pharmacotherapy; 2020. p. 121.
Jiang A, Zhou Y, Gong W, et al. CCNA2 as an immunological biomarker encompassing Tumor Microenvironment and therapeutic response in multiple Cancer Types[J]. Oxidative Med Cell Longev. 2022;2022:1–35.
Zhang C, Quan Y, Yang L, et al. 6-Methoxyflavone induces S-phase arrest through the CCNA2/CDK2/p21CIP1 signaling pathway in HeLa cells[J]. Bioengineered. 2022;13(3):7277–92.
Fang HC, Wu BQ, Hao YL, et al. KRT1 gene silencing ameliorates myocardial ischemia–reperfusion injury via the activation of the notch signaling pathway in mouse models[J]. J Cell Physiol. 2018;234(4):3634–46.
Box C, Pennington C, Hare S, et al. Brk/PTK6 and involucrin expression may predict breast Cancer cell responses to vitamin D3[J]. Int J Mol Sci. 2023;24:13.
Feng D, Lin J, Wang W et al. Wnt3a/β-Catenin/CBP activation in the progression of cervical intraepithelial Neoplasia[J]. Pathol Oncol Res. 2021, 27.
Dittmer J. Biological effects and regulation of IGFBP5 in breast cancer[J]. Front Endocrinol. 2022, 13.
Deng Y, Yang X, Hua H, et al. IGFBP5 is upregulated and Associated with Poor Prognosis in Colorectal Cancer[J]. Int J Gen Med. 2022;15:6485–97.
Zhou J, Liu X, Wang C et al. The correlation analysis of miRNAs and target genes in metastasis of cervical squamous cell carcinoma[J]. 2018, 10 (3):259–75.
Hou XJ, Zhang YZ, Liu X, et al. Expressions of IGFBP-5, cFLIP in cervical intraepithelial neoplasia, cervical carcinoma and their clinical significances: a molecular pathology[J]. J Exp Clin Cancer Res. 2009;28(1):70.
Chen P, Gu YY, Ma FC et al. Expression levels and co–targets of miRNA–126–3p and miRNA–126–5p in lung adenocarcinoma tissues: Αn exploration with RT–qPCR, microarray and bioinformatic analyses[J]. Oncol Rep. 2018.
Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer[J]. Dis Models Mech. 2021, 14 (4).
Wilting SM, Snijders PJF, Verlaat W, et al. Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis[J]. Oncogene. 2012;32(1):106–16.
Wang Y, Zhou S, Fan K, et al. MicroRNA–21 and its impact on signaling pathways in cervical cancer (review)[J]. Oncol Lett; 2019.
Wang Y, Xu B, Shen X et al. Diagnostic value of miR-153 and miR-203 in patients with cervical cancer and their correlation with human papillomavirus infection[J]. 2021, 13 (8):9736–42.
Yue J, Mao L, Zhang Y et al. BANF1 is downregulated by IRF1-Regulated MicroRNA-203 in cervical Cancer[J]. PLoS ONE. 2015, 10 (2).
Funding
This study was supported by Guidance Plan for Key Scientific Research Projects in Higher Education Institutions in Henan Province [20B320018].
Author information
Authors and Affiliations
Contributions
XM. Yang and XF. Yang were responsible for conception and design of this study, XM. Yang wrote the main manuscript text, XM. Yang and MS. Zhou collected and analyzed all datasets, MS. Zhou and YY. Luan prepared all figures. KH. Li interpreted the data, YF. Wang prepared supplementary materials. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Ethical approval
Ethical approval is not available for this article.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Yang, X., Zhou, M., Luan, Y. et al. Identification of key genes associated with cervical cancer based on bioinformatics analysis. BMC Cancer 24, 897 (2024). https://doi.org/10.1186/s12885-024-12658-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12885-024-12658-z